Literature DB >> 16301122

Pathologic findings and therapeutic outcome of desperation post-chemotherapy retroperitoneal lymph node dissection in advanced germ cell cancer.

Stephen D W Beck1, Richard S Foster, Richard Bihrle, Lawrence H Einhorn, John P Donohue.   

Abstract

Increased serum tumor markers after cisplatin-based chemotherapy have usually been considered a contraindication to surgery because of the presence of persistent active germ cell elements. However, a select population of patients with elevated serum tumor markers have undergone post-chemotherapy retroperitoneal lymph node dissection (RPLND) with curative intent. We evaluated the role of surgery to resect retroperitoneal-only marker positive tumor. Long-term survival was observed in 50% of patients. Residual germ cell cancer was identified in 50% of patients, with a third alive at 5 years with no observed benefit from adjuvant chemotherapy. Select patients with increased tumor markers after chemotherapy are cured with surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16301122     DOI: 10.1016/j.urolonc.2005.06.007

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  7 in total

1.  Management of residual mass in nonseminomatous germ cell tumors following chemotherapy.

Authors:  Siamak Daneshmand; Hooman Djaladat; Craig Nichols
Journal:  Ther Adv Urol       Date:  2011-08

Review 2.  Surgical salvage in patients with advanced testicular cancer: indications, risks and outcomes.

Authors:  Ryan W Speir; Clint Cary; Timothy A Masterson
Journal:  Transl Androl Urol       Date:  2020-01

Review 3.  Postchemotherapy surgery for germ cell tumors--what have we learned in 35 years?

Authors:  Stephen B Riggs; Earl F Burgess; Kris E Gaston; Caroline A Merwarth; Derek Raghavan
Journal:  Oncologist       Date:  2014-04-09

4.  Treatment at an Inexperienced Center Suggests Worse Prognosis of Metastatic Germ Cell Tumors.

Authors:  Hiroshi Yaegashi; Kouji Izumi; Suguru Kadomoto; Hiroaki Iwamoto; Masashi Iijima; Shohei Kawaguchi; Takahiro Nohara; Kazuyoshi Shigehara; Yoshifumi Kadono; Atsushi Mizokami
Journal:  Cancer Diagn Progn       Date:  2021-03-03

Review 5.  Platinum-refractory germ cell tumors: an update on current treatment options and developments.

Authors:  Christoph Oing; Winfried H Alsdorf; Gunhild von Amsberg; Karin Oechsle; Carsten Bokemeyer
Journal:  World J Urol       Date:  2016-07-23       Impact factor: 4.226

Review 6.  [Stage-specific treatment for testicular germ cell tumours].

Authors:  A Heidenreich; C Bokemeyer; R Souchon
Journal:  Urologe A       Date:  2009-04       Impact factor: 0.639

7.  SEOM clinical guidelines for the management of germ cell testicular cancer (2016).

Authors:  J Aparicio; J Terrasa; I Durán; J R Germà-Lluch; R Gironés; E González-Billalabeitia; J Gumà; P Maroto; A Pinto; X García-Del-Muro
Journal:  Clin Transl Oncol       Date:  2016-11-04       Impact factor: 3.405

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.